Back to Search
LEONARD SALTZ, MD
MD
Medical Oncology Physician
NPI: 1790756625IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
162425(NY)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
YALE UNIVERSITY SCHOOL OF MEDICINE
Class of 1983
Research & Publications (20)
Looking ahead: what will change in colorectal cancer treatment?
PMID 19461916·Gastrointest Cancer Res·2009
8-other
Colorectal Cancer Treatment: What's Next? (or: Is There Life After EGFR and VEGF?).
PMID 19343143·Gastrointest Cancer Res·2008
8-other
Second- and third-line treatment options for unresectable metastatic colorectal cancer.
PMID 19259281·Gastrointest Cancer Res·2008
5-case
Progress in cancer care: the hope, the hype, and the gap between reality and perception.
PMID 18794538·J Clin Oncol·2008
8-other
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
PMID 18421054·J Clin Oncol·2008
3-trial
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
PMID 17947727·J Clin Oncol·2007
3-trial
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
PMID 17876013·J Clin Oncol·2007
3-trial
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
PMID 17687149·J Clin Oncol·2007
2-rct
Planned treatment interruptions and chemotherapy-free intervals in the treatment of metastatic colorectal cancer: time to start stopping?
PMID 17178282·Semin Oncol·2006
6-review
Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?
PMID 16336755·Clin Colorectal Cancer·2005
8-other
Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
PMID 16264850·Nat Clin Pract Oncol·2005
3-trial
Metastatic colorectal cancer: is there one standard approach?
PMID 16255132·Oncology (Williston Park)·2005
6-review
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
PMID 14993230·J Clin Oncol·2004
3-trial
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
PMID 11161231·Oncologist·2001
3-trial
Oral chemotherapy for colorectal cancer: some economic considerations.
PMID 11219974·Oncology (Williston Park)·2001
4-observational
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
PMID 11006366·N Engl J Med·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10021 - Phone
- (212) 639-2000
Quick Facts
- NPI
- 1790756625
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 43
- Publications
- 20
Are you this provider?
Claim Your Profile